Loading clinical trials...

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging | Clinical Trials | Clareo Health

RECRUITINGNA

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

NCT06084195•Institut du Cancer de Montpellier - Val d'Aurelle

Summary

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

Detailed Description

After being informed about the study and potential risks, all patient giving wirtting informed consent. During surgery, tissue and blood samples will be conserved for the study. In this study will be compared images obtained in vivo before surgical management, ex vivo images obtained on excised tissues during surgery, histological data obtained during surgery.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patient aged \>18
•Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
•Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
•Patient who has given informed, written and express consent,
•Patient affiliated with a French health insurance scheme.

Exclusion Criteria

•Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
•Patient who will not have surgery
•Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
•Patient under guardianship, curatorship or safeguarding of justice,
•Pregnant and/or nursing patient,
•Patient with a history of other cancers within 5 years/10 years prior to inclusion

Locations (1)

NOUGARET Stephanie

Montpellier, France

Key Dates

Start Date

December 19, 2023

Primary Completion Date

October 1, 2026

Completion Date

October 1, 2029

Last Updated

February 12, 2025

Enrollment

120

ESTIMATED participants

Conditions

High Grade Serous Ovarian Cancer

Interventions

Blood sample and tissue sample

BIOLOGICAL

Contacts

MOUSSION Aurore

CONTACT

0467613102 aurore.moussion@icm.unicancer.fr

Texier Emmanuelle

CONTACT

0467613102 emmanuelle.texier@icm.unicancer.fr

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

NCT05512208

Endometrioid CancerMucinous Ovarian Cancer+3 more

View study

RECRUITING

Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma

NCT06777082

High Grade Serous Ovarian Cancer

View study

TERMINATED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Expanded Access to Veliparib

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors